Literature DB >> 22884782

Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.

Makoto Sugaya1, Tomomitsu Miyagaki, Hanako Ohmatsu, Hiraku Suga, Hiromichi Kai, Masahiro Kamata, Hideki Fujita, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Hitoshi Okochi, Shinichi Sato.   

Abstract

BACKGROUND: Classically activated macrophages produce IL-12, IL-23, and TNF-α, whereas alternatively activated macrophages (M2 cells) produce IL-10 and express several receptors such as mannose receptor and CD163. Tumor-associated macrophages exhibit M2 phenotype, whose presence has been associated with poor prognosis in various tumors.
OBJECTIVES: To investigate distribution of CD163(+) cells in lesional skin and serum levels of soluble CD163 (sCD163) in patients with cutaneous T cell lymphoma (CTCL), atopic dermatitis (AD), or psoriasis.
METHODS: The numbers of CD163(+) and CD68(+) cells in lesional skin of CTCL, AD, or psoriasis, and in normal skin were examined by immunohistochemistry. Serum soluble CD163 (sCD163) levels were quantified by enzyme-linked immunosorbent assay.
RESULTS: The numbers of CD163(+) cells in lesional skin of CTCL, AD, or psoriasis were significantly larger than in normal skin. In CTCL, the numbers of CD163(+) or CD68(+) cells increased as more tumor cells infiltrated and they decreased after treatment with topical steroid and ultraviolet light. Moreover, CTCL patients with an increased number of CD163(+) cells showed worse prognosis. Serum sCD163 levels in patients with CTCL, AD, or psoriasis were significantly higher than those in normal controls. In CTCL patients, serum sCD163 levels significantly correlated with serum soluble interleukin-2 receptor and CCL17 levels. In AD patients, serum sCD163 levels correlated with serum IgE levels.
CONCLUSION: The numbers of CD163(+) cells in lesional skin and serum sCD163 levels were associated with disease progression of CTCL. Further study focusing on CD163(+) cells in CTCL lesional skin would be an interesting research field.
Copyright © 2012 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884782     DOI: 10.1016/j.jdermsci.2012.07.007

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  35 in total

1.  IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Authors:  Hanako Ohmatsu; Daniel Humme; Juana Gonzalez; Nicholas Gulati; Markus Möbs; Wolfram Sterry; James G Krueger
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 2.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

3.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

4.  Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.

Authors:  Alyxzandria M Gaydosik; Dawn S Queen; Megan H Trager; Oleg E Akilov; Larisa J Geskin; Patrizia Fuschiotti
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

5.  Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice.

Authors:  Xuesong Wu; Timothy W Wang; George M Lessmann; Jamal Saleh; Xiping Liu; Christopher R Chitambar; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-11-05       Impact factor: 8.551

6.  CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma.

Authors:  Chaoya Ma; Hasita Horlad; Koji Ohnishi; Takenobu Nakagawa; Sohsuke Yamada; Shohei Kitada; Takanobu Motoshima; Tomomi Kamba; Toshiyuki Nakayama; Naohiro Fujimoto; Motohiro Takeya; Yoshihiro Komohara
Journal:  Med Mol Morphol       Date:  2017-07-07       Impact factor: 2.309

7.  IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization.

Authors:  Hanako Ohmatsu; Daniel Humme; Nicholas Gulati; Juana Gonzalez; Markus Möbs; Mayte Suárez-Fariñas; Irma Cardinale; Hiroshi Mitsui; Emma Guttman-Yassky; Wolfram Sterry; James G Krueger
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

8.  GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

Authors:  Tianjiao Wang; Andrew L Feldman; David A Wada; Ye Lu; Avery Polk; Robert Briski; Kay Ristow; Thomas M Habermann; Dafydd Thomas; Steven C Ziesmer; Linda E Wellik; Thomas M Lanigan; Thomas E Witzig; Mark R Pittelkow; Nathanael G Bailey; Alexandra C Hristov; Megan S Lim; Stephen M Ansell; Ryan A Wilcox
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

Review 9.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

Review 10.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.